Talaris Therapeutics, Inc. is a late-clinical stage, cell therapy company. The Company is engaged in developing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Its therapeutic approach, allo-HSCT therapy prevents organ rejection without the morbidity and mortality that has been associated with the use of anti-rejection medicines, also known as chronic immunosuppression. Allo-HSCT is used to replace diseased immune, blood or stem cells in patients with severe immune, blood or metabolic disorders. The Company’s lead product candidate, FCR001, which is central to its Facilitated Allo-HSCT Therapy, is an allogeneic cell therapy comprised of stem and immune cells that are procured from a healthy donor, who is also the organ donor in the case of organ transplantation. It is advancing a pipeline of programs across three therapeutic categories: solid organ transplantation, severe autoimmune disease, and severe non-malignant blood, immune and metabolic disorders.